Praxis Precision Medicines, Inc. (PRAX) Earnings History
Net Loss8 years of earnings data (2018–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Praxis Precision Medicines, Inc. (PRAX) Earnings Overview
As of June 23, 2026, Praxis Precision Medicines, Inc. (PRAX) reported trailing twelve-month net income of -$327M, reflecting -32.0% year-over-year growth. The company earned $-11.31 per diluted share over the past four quarters.
Looking at the long-term picture, PRAX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$27M in fiscal 2018.
Praxis Precision Medicines, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ACAD ($376M net income, 36.5% margin), NRIX (-$264M net income, -314.9% margin), ARVN (-$221M net income, -30.8% margin), PRAX has comparable earnings metrics. Compare PRAX vs ACAD →
PRAX Earnings vs Peers
Earnings metrics vs comparable public companies
PRAX Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$303M | -65.9% | -$326M | $-13.48 | - | - |
| 2024 | -$183M | -48.3% | -$200M | $-10.21 | -2137.5% | -2340.3% |
| 2023 | -$123M | +42.4% | -$126M | $-18.69 | -5037.9% | -5164.4% |
| 2022 | -$214M | -28.1% | -$215M | $-69.33 | - | - |
| 2021 | -$167M | -170.2% | -$167M | $-58.96 | - | - |
| 2020 | -$62M | -74.1% | -$62M | $-103.61 | - | - |
| 2019 | -$36M | -33.8% | -$36M | $-348.24 | - | - |
| 2018 | -$27M | - | -$23M | $-306.73 | - | - |
Download Data
Export PRAX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
PRAX — Frequently Asked Questions
Quick answers to the most common questions about buying PRAX stock.
What is PRAX earnings per share (EPS)?
PRAX trailing twelve-month (TTM) diluted EPS is $-11.31, reflecting -32.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2025 is available in the table on this page.
What is Praxis Precision Medicines, Inc.'s net income?
Praxis Precision Medicines, Inc. (PRAX) trailing twelve-month net income is $-327M as of 2025. Earnings declined -32.0% year-over-year.
Is PRAX profitable?
PRAX is not currently profitable on a TTM basis, reporting a net loss of $-327M. Net margin is N/A. Investors should monitor for a return to profitability.
What is PRAX's earnings growth rate?
PRAX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2025.
What are PRAX's profit margins?
Praxis Precision Medicines, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -45.8%.
Is PRAX growing earnings?
PRAX earnings are declining — EPS fell -32.0% year-over-year. TTM net income dropped to $-327M. This contrasts with the 5-year CAGR of N/A.
What was PRAX's best earnings year?
Praxis Precision Medicines, Inc.'s highest annual net income on record is $-27M, achieved in fiscal year 2018. Earnings history on this page spans 2018 to 2025 and includes all annual and quarterly figures.
What were PRAX's earnings last quarter?
PRAX's most recent reported quarter was Q1 2026. Net income was $-93M with diluted EPS of $-3.20. For a full breakdown of all quarters, see the quarterly earnings table on this page.